Apellis Pharma Sustainability Profile
Apellis Pharmaceuticals, often referred to simply as Apellis, is a leading biopharmaceutical company headquartered in the United States. Founded in 2009, the company has made significant strides in the field of complement biology, focusing on innovative therapies for rare diseases and serious conditions. With a strong operational presence in North America and Europe, Apellis is dedicated to transforming the treatment landscape for patients with unmet medical needs. The company’s flagship product, pegcetacoplan, is a groundbreaking therapy designed to address conditions such as paroxysmal nocturnal haemoglobinuria (PNH) and geographic atrophy (GA) associated with age-related macular degeneration. Apellis stands out in the industry for its commitment to advancing complement inhibition, positioning itself as a pioneer in this specialised area. With a robust pipeline and a focus on patient-centric solutions, Apellis Pharmaceuticals continues to solidify its reputation as a key player in the biopharmaceutical sector.
DitchCarbon Score
How does Apellis Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Apellis Pharma's score of 25 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Apellis Pharma's reported carbon emissions
Apellis Pharma, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges available from the company. As a result, Apellis Pharma's climate commitments and initiatives remain unclear, and there is no inherited emissions data from a parent company or corporate family. The company may still be in the process of developing its sustainability strategies or reporting frameworks. In the context of the pharmaceutical industry, many companies are increasingly focusing on reducing their carbon footprints and setting science-based targets to align with global climate goals. However, without specific data or commitments from Apellis Pharma, it is challenging to assess their current standing in this regard.
How Carbon Intensive is Apellis Pharma's Industry?
How Carbon Intensive is Apellis Pharma's Location?
Apellis Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Apellis Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
